NCT04080804 2026-04-22
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT04953104 2026-04-15
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05347212 2026-04-15
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03044613 2026-03-23
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT03607890 2026-03-16
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT05418972 2026-02-05
Neo ReNi II
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT06880549 2026-02-05
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT05034536 2026-01-08
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03610711 2025-12-22
REACTION
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Active not recruiting
NCT04658147 2025-12-18
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04623775 2025-10-20
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT03470922 2025-09-09
RELATIVITY-047
Bristol-Myers Squibb
Phase 2/3 Active not recruiting
NCT05625399 2025-08-24
RELATIVITY-127
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03867799 2024-06-14
iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting